GNPX Stock Price, Genprex Inc Quote, Chart

Market Summary

USD2.21+0.09

Market Closed

4.25%

GNPX Stock Price

View Fullscreen

GNPX RSI Chart

GNPX Valuation

Market Cap

131.4M

Price/Earnings (Trailing)

-4.26

Price/Free Cashflow

-5.31

GNPX Price/Sales (Trailing)

GNPX Profitability

Return on Equity

-416.11%

Return on Assets

-289.21%

Free Cashflow Yield

-18.83%

GNPX Fundamentals

GNPX Earnings

Earnings (TTM)

-30.9M

Earnings Growth (Yr)

9.11%

Earnings Growth (Qtr)

23.48%

Breaking Down GNPX Revenue

Last 7 days

3.8%

Last 30 days

-18.4%

Last 90 days

-76.3%

Trailing 12 Months

-93.3%

How does GNPX drawdown profile look like?

GNPX Financial Health

Current Ratio

2.31

GNPX Investor Care

Shares Dilution (1Y)

23.76%

Tracking the Latest Insider Buys and Sells of Genprex Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 18, 2024	varner john rodney	sold (taxes)	-11,624	4.4	-2,642	chairman, president and ceo
Feb 18, 2024	confer ryan m.	sold (taxes)	-4,954	4.4	-1,126	chief financial officer
Feb 18, 2024	berger mark stanley	sold (taxes)	-5,803	4.4	-1,319	chief medical officer
Jun 27, 2023	wilson william r jr.	acquired	-	-	123,795	-
Jun 27, 2023	moreno toscano jose antonio	acquired	-	-	123,795	-
Jun 27, 2023	longnecker brent m	acquired	-	-	123,795	-
Apr 21, 2023	varner john rodney	bought	20,045	1.055	19,000	chairman, president and ceo
Apr 21, 2023	vaczy catherine m	bought	21,478	1.0739	20,000	evp gc chief strategy officer
Feb 18, 2023	varner john rodney	acquired	-	-	625,000	president & ceo
Feb 18, 2023	kumar hermant	acquired	-	-	200,000	chief mfgr & tech officer

Which funds bought or sold GNPX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Bank of New York Mellon Corp	sold off	-100	-4,041	-	-%
Apr 15, 2024	Visionary Horizons, LLC	sold off	-100	-6,900	-	-%
Mar 11, 2024	VANGUARD GROUP INC	unchanged	-	-301,206	420,118	-%
Feb 26, 2024	Virtu Financial LLC	sold off	-100	-24,000	-	-%
Feb 14, 2024	CITADEL ADVISORS LLC	added	1,665	39,699	43,975	-%
Feb 14, 2024	STATE STREET CORP	unchanged	-	-28,435	39,661	-%
Feb 14, 2024	Royal Bank of Canada	added	14.17	-	1,000	-%
Feb 14, 2024	SILVERCREST ASSET MANAGEMENT GROUP LLC	unchanged	-	-9,234	12,880	-%
Feb 14, 2024	MILLENNIUM MANAGEMENT LLC	new	-	6,492	6,492	-%
Feb 14, 2024	TWO SIGMA SECURITIES, LLC	added	16.32	-2,287	4,802	-%

Are Funds Buying or Selling GNPX?

Are funds buying GNPX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own GNPX

No. of Funds

Unveiling Genprex Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	cvi investments, inc.	4.9%	3,089,092	SC 13G/A
Jul 24, 2023	cvi investments, inc.	5.8%	3,465,347	SC 13G
Feb 19, 2021	altium capital management lp	5.1%	2,400,000	SC 13G/A
Feb 16, 2021	cvi investments, inc.	-	0	SC 13G/A
Feb 16, 2021	altium capital management lp	3.3%	1,409,785	SC 13G/A
Feb 09, 2021	hudson bay capital management lp	0%	0	SC 13G/A
Jan 04, 2021	sabby management, llc	12.%	0	SC 13G/A
Dec 28, 2020	altium capital management lp	7.2%	3,116,884	SC 13G
Feb 19, 2020	roth jack a	6.0%	1,155,128	SC 13G/A
Feb 14, 2020	ly viet-an hoan	5.7%	1,169,845	SC 13G/A

Recent SEC filings of Genprex Inc

View All Filings

Date Filed	Form Type	Document
Apr 17, 2024	S-8	Employee Benefits Plan
Apr 01, 2024	10-K	Annual Report
Mar 20, 2024	8-K	Current Report
Mar 20, 2024	424B5	Prospectus Filed
Mar 06, 2024	8-K	Current Report
Feb 26, 2024	8-K	Current Report
Feb 21, 2024	4	Insider Trading
Feb 21, 2024	4	Insider Trading
Feb 21, 2024	4	Insider Trading
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Genprex Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Genprex Inc News

Latest updates

Genprex Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-35.9%	11.00	17.00	16.00	23.00	25.00	30.00	35.00	39.00	43.00	46.00	49.00	51.00	31.00	23.00	25.00	25.00	4.00	4.00	6.00	7.00	9.00
Current Assets	-41.4%	8.00	13.00	12.00	20.00	21.00	26.00	31.00	36.00	39.00	46.00	48.00	50.00	28.00	23.00	24.00	24.00	3.00	4.00	6.00	7.00	9.00
Cash Equivalents	-42.5%	7.00	12.00	10.00	18.00	21.00	26.00	30.00	35.00	39.00	42.00	44.00	47.00	27.00	21.00	22.00	23.00	2.00	3.00	4.00	7.00	9.00
Net PPE	-31.4%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-	-	-	-	-	-	2.00	2.00	2.00	2.00	-	-	-	-	-	-	-	-	-	-	-	-
Current Liabilities	-25.0%	3.00	4.00	4.00	5.00	3.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	0.00	0.00
Shareholder's Equity	-39.7%	7.00	12.00	12.00	18.00	22.00	27.00	32.00	37.00	41.00	45.00	48.00	50.00	31.00	23.00	25.00	24.00	3.00	4.00	5.00	7.00	9.00
Retained Earnings	-4.6%	-133	-127	-120	-112	-102	-96.30	-90.16	-84.40	-79.09	-72.34	-68.90	-64.91	-58.42	-53.19	-50.42	-46.05	-40.48	-38.05	-35.68	-31.98	-29.82
Additional Paid-In Capital	0.8%	141	140	132	130	125	124	123	121	120	117	117	115	89.00	76.00	75.00	70.00	43.00	42.00	41.00	39.00	39.00
Shares Outstanding	-100.0%	-	59.00	52.00	52.00	48.00	48.00	48.00	48.00	48.00	47.00	46.00	46.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	-	66.00	-	-	-	151	-	-	-	114	-	-	-	30.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-4.8%	-4,963	-4,735	-8,107	-6,932	-4,704	-4,522	-4,480	-4,071	-3,218	-2,634	-2,966	-5,465	-3,892	-2,015	-3,510	-4,517	-1,721	-1,989	-1,565	-1,641	-2,061
Share Based Compensation	-30.2%	1,040	1,490	1,546	1,332	1,305	1,218	1,151	1,057	2,863	675	1,137	672	674	448	2,371	754	650	582	1,775	523	1,613
Cashflow From Investing	54.8%	-9.83	-21.76	-20.00	-19.63	137	-16.05	-21.85	-1.84	-173	168	32.00	-110	-2,341	153	-11.29	-137	-91.77	42.00	-883	-13.33	-63.89
Cashflow From Financing	-100.0%	10*	6,513	-	4,081	5.00	2.00	-	-	-	244	110	25,324	12,495	794	2,569	25,732	-	-	-	-	417

GNPX Income Statement

2023-12-31

Statements of Operations - USD ($)	12 Months Ended
Statements of Operations - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Revenues	$ 0	$ 0
Cost and expenses:
Depreciation	15,004	25,575
Research and development	17,616,605	11,510,074
General and administrative	13,443,961	12,295,070
Total costs and expenses	31,075,570	23,830,719
Operating loss	(31,075,570)	(23,830,719)
Interest income	215,109	90,098
Net loss	$ (30,860,461)	$ (23,740,621)
Net loss per share — basic and diluted (in dollars per share)	$ (22.56)	$ (19.8)
Weighted average number of common shares — basic and diluted (in shares)	1,367,747	1,198,837

GNPX Balance Sheet

2023-12-31

Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 6,737,629	$ 20,954,069
Accounts receivable	0	34,852
Prepaid expenses and other	794,138	484,224
Total current assets	7,531,767	21,473,145
Property and equipment, net	7,859	23,032
Other assets:
Security deposits	10,000	21,818
Research and development supplies	2,347,488	2,864,937
Intellectual property, net	773,478	702,095
Total other assets	3,130,966	3,588,850
Total assets	10,670,592	25,085,027
Current liabilities:
Accounts payables	1,397,610	442,925
Other current liabilities	1,856,598	2,367,362
Total current liabilities	3,254,208	2,810,287
Stockholders' equity:
Common stock $0.001 par value: 200,000,000 shares authorized; 1,485,902 and 1,202,677 shares issued and outstanding, respectively	1,486	1,203
Additional paid-in capital	141,103,178	125,101,356
Accumulated deficit	(133,688,280)	(102,827,819)
Total stockholders' equity	7,416,384	22,274,740
Total liabilities and stockholders' equity	$ 10,670,592	$ 25,085,027

About Genprex Inc

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

CEO	Mr. John Rodney Varner
WEBSITE	genprex.com
INDUSTRY	Biotechnology
EMPLOYEES	30

Genprex Inc Frequently Asked Questions

What is the ticker symbol for Genprex Inc? What does GNPX stand for in stocks?

GNPX is the stock ticker symbol of Genprex Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Genprex Inc (GNPX)?

As of Fri Apr 26 2024, market cap of Genprex Inc is 131.35 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GNPX stock?

You can check GNPX's fair value in chart for subscribers.

What is the fair value of GNPX stock?

You can check GNPX's fair value in chart for subscribers. The fair value of Genprex Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Genprex Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GNPX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Genprex Inc a good stock to buy?

The fair value guage provides a quick view whether GNPX is over valued or under valued. Whether Genprex Inc is cheap or expensive depends on the assumptions which impact Genprex Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GNPX.